Danaher Corporation · NYSE:DHR
Danaher — Conference Presentation (January 2023)
9 slides from Danaher's conference presentation, Jan 9, 2023
Slide 1: Forward Looking Statements
Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding Danaher’s anticipated financial performance and any other statements regarding events or developments that we believe or anticipate will or may occur are "forward-looking"
Slide 2: Reconciliation of GAAP to Non-GAAP Financial Measures
DANAHER CORPORATION RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES Estimated Sales Growth, Core Sales Growth and Base Business Core Sales Growth ‘% Estimated Change Three Month Period Ended December 31, 2022 vs, Comparable 2031 Perlod Total sales growth (GAAP) +Low-single digit Impact of: Acq
Slide 3: Current Update
Current Update 3 Strong finish to 2022 with Q4 results exceeding expectations Q4 2022 ESTIMATED CORE REVENUE GROWTH UP HIGH-SINGLE DIGITS — High-single digit base business core revenue growth as expected — Better-than-expected respiratory testing revenue at Cepheid — Anticipate respiratory testing r
Slide 4: Environmental & Applied Solutions Separation
Environmental & Applied Solutions Separation A global leader in Water Quality and Product Identification MSD CORE REVENUE GROWTH ~55% RECURRING REVENUE ~25% ADJUSTED EBITDA MARGIN ANTICIPATED BUSINESS PROFILE • Leading positions and outstanding brands, foundation built on DBS • Attractive financial
Slide 5: Danaher 2024+: A Focused Science & Technology Leader
5 DIAGNOSTICS: ~$10.8B 2022E REVENUE *Anticipated long-term core revenue growth rate Pie chart reflects FY 2022E revenue by product line Danaher 2024+: A Focused Science & Technology Leader Outstanding businesses focused on impacting human health MSD* CLINICAL LDD* MOLECULAR HSD* PATHOLOGY & ACUTE /
Slide 6: Cytiva's Progress Since Acquisition
Cytiva’s Progress Since Acquisition AT ACQ. 2022E Revenue ~$3B >$6B Anticipated long-term core revenue growth +6-7% +HSD ROIC +DD Exceeding expectations on all fronts RESULTS SINCE ACQUISITIONKEY PRIORITIES & PROGRESS SINCE ACQUISITION Stand-up & Brand Establishment >3,000 ASSOCIATES HIRED BRAND POW
Slide 7: Biotechnology: Aligning to best serve our customers
Biotechnology Aligning to best serve our customers 2022E TOTAL REVENUE Life Sciences Research Lab & Medical 7 BROADEST PORTFOLIO ACROSS BIOPROCESSING WORKFLOW • Leading positions in upstream & downstream applications • Single-use technologies (SUT) >$1B 2022E revenue BEST-IN-CLASS TECHNICAL SERVICE
Slide 8: Accelerating Innovation Across Life Sciences
MSD HSD LSD HSD/LDD LSD MSD>40% INCREASE IN REVENUE FROM NEW PRODUCTS LAST 3 YEARS PRODUCT LAUNCH EXCELLENCE AT Accelerating Innovation Across Life Sciences DBS GROWTH TOOLS INCREASING THE CADENCE OF INNOVATION >30 NEW PRODUCTS LAUNCHED SINCE 2018 ACCELERATED PRODUCT DEVELOPMENT AT 2021 REVENUE GROW
Slide 9: Danaher 2024+: Putting It All Together
Danaher 2024+: Putting It All Together Now expect HSD long-term core revenue growth CORE REVENUE GROWTH HSD FALL-THROUGH 35-40% STRONG FREE CASH FLOW >100% FCF / NI ACQUISITIONS FCF+ M&A SPEND TOP QUARTILE EPS GROWTH & COMPOUNDING RETURNS DD+ EPS GROWTH + + = + DANAHER HSD HSD 2022E revenue of ~$8.8